Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Azur Pharma, Inc
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with treatment-resistant schizophrenia currently being treated with Clozaril or generic clozapine for at least 3 months
Patients with treatment-resistant schizophrenia who failed to respond adequately to treatment with at least 2 courses of standard drug treatments for schizophrenia, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs
Males and females of 18 years of age or older
Females of childbearing potential using a reliable form of contraception
Ability to comply with the required WBC/ANC monitoring schedule
Ability to follow physician's instructions
Signed informed consent by patient or legal guardian
You may not be if
Phenylketonurics
Females of childbearing potential not using a reliable form of contraception
Women who are pregnant or want to become pregnant
Nursing
Patients allergic to clozapine or any othe ingredient contained in FazaClo tablets
Patients who have previously experienced a severe adverse reaction to clozapine
Patients previously excluded from taking clozapine due to a higher risk of developing white blood cell disorders
Clinical significant medical condition that the physician believes may increase the patient's risk of participating int he study (e.g., severe cardiac disorder, epilepsy)
Concomitant medications that may be contraindicated with FazaClo
Patients who have been taking FazaCLo within the last three months
Patients unable to comply with the required WBC/ANC monitoring schedule
Patients unable to follow the physician's instructions
Patients unable or unwilling to provide Informed Consent
Clareo Health | FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
